Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanaomycin D is a small molecule antibiotic belonging to the benzoisochromanequinone class of polyketides and is produced by certain Streptomyces species such as Streptomyces rosa[1][2][3]. It exhibits antibacterial activity and has been studied primarily as an experimental compound rather than a clinically approved drug[1][8]. Nanaomycin D’s mechanism of action is not fully elucidated but it acts as an antibiotic with reported activity against bacteria and fungi[8][9]. It has also been listed in pharmaceutical compound libraries for research purposes but lacks clinical approval or established therapeutic indications in humans[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nanaomycin d.